Analyst: Novo Nordisk's year may start with zero growth
Last year's stockpiling at the start of the covid-19 pandemic provides difficult grounds for comparison for Novo Nordisk, which publicizes its Q1 report on Wednesday.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN & CATHERINE BRETT
Although covid-19 restrictions are slowly easing up, Danish financial institution Sydbank believes that pharmaceutical company Novo Nordisk's growth will be kept down by the crisis.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
